Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy

Abstract

Bevacizumab (BV) prolongs the survival of colorectal cancer patients when combined with irinotecan (CPT-11)-based regimens. In the AVF2107g study, the area under the curve (AUC) ratio for bolus CPT-11/5-fluorouracil (5-FU)/leucovorin (LV) (IFL) with the BV arm to bolus IFL with placebo indicated that SN-38 concentrations may have been increased in subjects… (More)
DOI: 10.1007/s00280-009-1051-4

Topics

7 Figures and Tables

Cite this paper

@article{Horita2009EffectsOB, title={Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy}, author={Yosuke Horita and Yutaka Yamada and Yutaro Hirashima and K. Kato and T. Nakajima and Takayo Hamaguchi and Y. Shimada}, journal={Cancer Chemotherapy and Pharmacology}, year={2009}, volume={65}, pages={467-471} }